ClinicalTrials.gg
CompletedNCT02232802Updated Oct 20, 2020Results posted

Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.

A Phase 1 interventional study of Enoxaparin Sodium and Enoxaparin Sodium in Enoxaparin Sodium is Administered to Healthy Volunteers, sponsored by Chemi S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-20.

Sponsored by Chemi S.p.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

  • The primary objective of the trial is to assess the single-dose relative bioavailability of Chemi Enoxaparin (80 mg/0.8 mL) and Clexane® (80 mg/0.8 mL) administered by subcutaneous (s.c.) injection, under fasting conditions in healthy volunteers.
  • The secondary objective of the trial is to assess safety and tolerability of Chemi Enoxaparin (80 mg/0.8 mL) and Clexane® (80 mg/0.8 mL) administered by s.c. injection, under fasting conditions in healthy volunteers.
Read the detailed description

This is an open-label, randomised, single-dose, 2-way crossover study to determine the comparative bioavailability of enoxaparin sodium from the Chemi Enoxaparin s.c. (80 mg/0.8mL) with that from the reference IMP, Clexane® s.c. (80 mg/0.8mL), following single dose administration in healthy male and female subjects.

Each subject received each treatment over two separate treatment periods under fasting conditions. Each dosing day for male subjects will be separated by a washout period of at least 7 days. The study comprised a pre-study screen (within 14 days of the first dose), followed by 2 Treatment Periods (1 and 2). During each treatment period, subjects will reside at Simbec from the evening before dosing (Day 1), until at least 36 h post dose (evening of Day 2). On admission (Day -1), subjects will provide a urine sample for a drugs of abuse screen; this sample will also be tested to confirm a negative pregnancy result in female volunteers.

A single dose of the randomised treatment will be given on the morning of Day 1 following an overnight fast and blood PK/PD samples collected from pre-dose up to 36 h post dose (14 samples). Safety will also be evaluated at specified times throughout the study.

The post study visit will be conducted on Day 2 (36 h post-dose) of Treatment Period 2.

02

Conditions studied

  • Enoxaparin Sodium is Administered to Healthy Volunteers
03

In context

Lead sponsor

Chemi S.p.A. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female volunteer between 18 and 55 years of age.
  • Subject with a of 18-30 (Body Mass Index = Body weight (kg) / [Height (m)]2)
  • Subject with no abnormal serum biochemistry, haematology, coagulation factors and urine examination values within 14 days of the first dose.
  • Subject with no clinically significant abnormalities in 12-lead (ECG) and vital signs determined within 14 days of the first dose.
  • Subject with negative (HIV) and surface antigen (HbsAg) and virus antibody (HCV) results.

Exclusion criteria

Exclusion Criteria:

  • Subject with or idiosyncratic reaction to enoxaparin and/or low molecular weight heparins, and/or pork products.
  • Subject with a relevant history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. Or with history or presence of alcoholism or drug abuse;
  • Subject with abnormal physical findings or clinically relevant abnormal laboratory values indicative of physical illness;
  • Female subject who is pregnant or lactating
  • Female subject with weight \< 45 kg or male subject with weight \< 57 kg.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Enoxaparin Sodium Chemi

    Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.

    Drug: Enoxaparin Sodium

  • Experimental
    Clexane

    Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.

    Drug: Enoxaparin Sodium

Interventions

  • comparison of bioavailability of generic Enoxaparin Sodium and Clexane

    Also known as: Clexane

  • comparison of bioavailability of generic Enoxaparin Sodium and Clexane

    Also known as: generic Enoxaparin Sodium

06

What researchers measure

Primary outcomes

  1. Cmax (Anti-FXa and Anti-FIIa)

    Cmax is the maximum measured plasma activity/concentration. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  2. AUC0-t (Anti-FXa and Anti-FIIa)

    AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII). thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

Secondary outcomes

  1. AUC0-inf (Anti-FXa and Anti-FIIa)

    AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  2. Tmax (Anti-FXa and Anti-FIIa)

    Tmax is the time to Cmax. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti-FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  3. Lambda Zeta (Anti-FXa and Anti-FIIa)

    Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  4. t1/2 (Anti-FXa and Anti-FIIa)

    T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  5. Tmin (Anti-FXa and Anti-FIIa)

    Tmin is the time of Cmin. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  6. AUC%ex (Anti-FXa and Anti-FIIa)

    AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti-FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  7. Cmin (Anti-FXa and Anti-FIIa)

    Cmin is the minimum plasma activity/concentration. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  8. Cmax (Tissue Factor Pathway Inhibitor, TFPI)

    Cmax is the maximum measured plasma activity/concentration. Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  9. Cmax (Anti-FXa/Anti-FIIa Ratio)

    Cmax is the maximum measured plasma activity/concentration. The ratio of anti-FXa/anti-FIIa activity was calculated for each parameter. Reults are presented as derived ratio of PK parameters.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  10. AUC0-t (Derived Thrombin Generation)

    AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method. Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  11. Cmin (Derived Thrombin Generation)

    Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample. Cmin is the minimum plasma activity/concentration.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  12. Tmin (Derived Thrombin Generation)

    Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample. Tmin is the time of Cmin.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  13. AUC0-t (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  14. AUC0-inf (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  15. Tmax (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Tmax is the time to Cmax

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  16. Cmin (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Cmin is the minimum plasma activity/concentration.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  17. Tmin (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Tmin is the time of Cmin.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  18. T1/2 (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  19. Lambda Zeta (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also releases tissue factor pathway inhibitor (TFPI)\[5\], which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  20. AUC%ex (Tissue Factor Pathway Inhibitor, TFPI)

    Enoxaparin also release tissue factor pathway inhibitor (TFPI)\[5\], which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  21. AUC0-t (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  22. AUC0-inf (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  23. T1/2 (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  24. Cmin (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Cmin is the minimun plasma activity/concentration.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  25. Tmin (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Tmin is the time of Cmin.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  26. AUC%ex (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  27. Tmax (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Tmax is the time to Cmax.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

  28. Lambda Zeta (Anti-FXa/Anti-FIIa Ratio)

    The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve.

    Time frame: At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)

07

Results

Posted Oct 20, 2020

Participant flow

Forty-seven (47) subjects (23 male and 24 female) were enrolled in the study. The subjects were selected from a large panel who offered their services as healthy volunteers for the purpose of undertaking REC and Regulatory Authority-approved studies on drug safety, absorption and disposition.

Period 1
Participant flow — Period 1
MilestoneTest IMP - Reference IMPReference IMP - Test IMP
Started2423
Completed2222
Not completed21
Withdrew: Sponsor request10
Withdrew: Adverse event11
Washout
Participant flow — Washout
MilestoneTest IMP - Reference IMPReference IMP - Test IMP
Started2222
Completed2222
Not completed00
Period 2
Participant flow — Period 2
MilestoneTest IMP - Reference IMPReference IMP - Test IMP
Started2222
Completed2222
Not completed00
Washout
Participant flow — Washout
MilestoneTest IMP - Reference IMPReference IMP - Test IMP
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryCmax (Anti-FXa and Anti-FIIa)

Cmax is the maximum measured plasma activity/concentration. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · IU/mL
Cmax (Anti-FXa and Anti-FIIa)
IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa0.8593 ± 0.180560.8698 ± 0.20921
Anti-thrombin/factor IIa0.1187 ± 0.034510.1296 ± 0.03713
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean difference ratio: 99.42 · 95% CI 96.28 to 102.65Geometric least square means are being compared.
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean difference ratio: 91.55 · 95% CI 86.65 to 96.73Geometric least square means are being compared.
PrimaryAUC0-t (Anti-FXa and Anti-FIIa)

AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII). thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*IU/mL
AUC0-t (Anti-FXa and Anti-FIIa)
h*IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa9.6259 ± 1.685909.3927 ± 1.83943
Anti-FIIa1.0234 ± 0.288171.1097 ± 0.31668
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean difference ratio: 102.89 · 95% CI 100.67 to 105.15Geometric least square means are being compared.
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean difference ratio: 92.37 · 95% CI 87.72 to 97.25Geometric least square means are being compared.
SecondaryAUC0-inf (Anti-FXa and Anti-FIIa)

AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*IU/mL
AUC0-inf (Anti-FXa and Anti-FIIa)
h*IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa10.2789 ± 1.713779.9197 ± 1.86143
Anti-FIIa1.1489 ± 0.292431.2926 ± 0.40401
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean ratio: 104.26 · 95% CI 101.68 to 106.9Geometric least square means are being compared.
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Least square mean ratio: 90.44 · 95% CI 85.38 to 95.8Geometric least square means are being compared.
SecondaryTmax (Anti-FXa and Anti-FIIa)

Tmax is the time to Cmax. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti-FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Median · Hours
Tmax (Anti-FXa and Anti-FIIa)
HoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa4.0000 (2.000 to 6.000)4.0000 (3.000 to 6.000)
Anti-FIIa4.0000 (2.000 to 6.000)4.0000 (3.000 to 16.000)
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Wilcoxon (Mann-Whitney) · p = 0.7642 (An assessment of tmax was performed using the Wilcoxon matched pairs test. In addition, a 95 % non-parametric CI was constructed for the median difference in tmax based on the method of Campbell and Gardner.) · Least square mean ratio: 0 · 95% CI -0.5 to 0.5Geometric least square means are being compared.
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Wilcoxon (Mann-Whitney) · p = 0.9464 · Least square mean ratio: 0 · 95% CI -0.5 to 0.5Geometric least square means are being compared.
SecondaryLambda Zeta (Anti-FXa and Anti-FIIa)

Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · 1/hour
Lambda Zeta (Anti-FXa and Anti-FIIa)
1/hourEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa0.0962 ± 0.042510.1133 ± 0.04337
Anti-IIa0.2111 ± 0.104350.1938 ± 0.11612
Secondaryt1/2 (Anti-FXa and Anti-FIIa)

T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
t1/2 (Anti-FXa and Anti-FIIa)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa8.4757 ± 3.227376.9507 ± 2.42567
Anti-FIIa4.6214 ± 2.979716.5045 ± 8.67539
SecondaryTmin (Anti-FXa and Anti-FIIa)

Tmin is the time of Cmin. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmin (Anti-FXa and Anti-FIIa)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa0.00 ± 0.0000.00 ± 0.000
Anti-FIIa4.18 ± 8.5386.91 ± 12.211
SecondaryAUC%ex (Anti-FXa and Anti-FIIa)

AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity. Blood samples (2 x 10 mL) for determination of plasma anti-FIIa and anti-FXa were collected from a forearm vein into a Citrate Sarstedt Monovette at the following time-points (at day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)) and kept frozen until analysis. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti-FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · percentage of total value of AUC
AUC%ex (Anti-FXa and Anti-FIIa)
percentage of total value of AUCEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa6.4515 ± 2.681304.9683 ± 1.80897
Anti-FIIa12.0593 ± 7.6884212.0906 ± 9.02925
SecondaryCmin (Anti-FXa and Anti-FIIa)

Cmin is the minimum plasma activity/concentration. Enoxaparin exerts its anti-coagulant effect primarily via interaction with anti-thrombin III (ATIII), thereby enhancing the inhibitory effect of ATIII on activated factor Xa (FXa) and thrombin/factor IIa (FIIa). As enoxaparin cannot be measured directly in blood, the PK of enoxaparin have been studied on the basis of its effect on clotting mechanisms, particularly the inhibition of FXa (anti-FXa) and FIIa (anti- FIIa) activity. Results are presented as derived plasma PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · IU/mL
Cmin (Anti-FXa and Anti-FIIa)
IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Anti-FXa0.000 ± 0.00000.000 ± 0.0000
Anti-FIIa0.002 ± 0.00440.002 ± 0.0042
SecondaryCmax (Tissue Factor Pathway Inhibitor, TFPI)

Cmax is the maximum measured plasma activity/concentration. Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · IU/mL
Cmax (Tissue Factor Pathway Inhibitor, TFPI)
IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Cmax (Tissue Factor Pathway Inhibitor, TFPI)2.4327 ± 0.359982.3391 ± 0.33903
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 103.94 · 95% CI 101.22 to 106.73
SecondaryCmax (Anti-FXa/Anti-FIIa Ratio)

Cmax is the maximum measured plasma activity/concentration. The ratio of anti-FXa/anti-FIIa activity was calculated for each parameter. Reults are presented as derived ratio of PK parameters.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · ratio
Cmax (Anti-FXa/Anti-FIIa Ratio)
ratioEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Cmax (Anti-FXa/Anti-FIIa Ratio)7.4450 ± 1.049836.8546 ± 0.95651
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 108.59 · 95% CI 103.93 to 113.46
SecondaryAUC0-t (Derived Thrombin Generation)

AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method. Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*nM
AUC0-t (Derived Thrombin Generation)
h*nMEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC0-t (Derived Thrombin Generation)3731.0710 ± 1375.972983597.3375 ± 1104.52084
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 102.76 · 95% CI 97.51 to 108.28
SecondaryCmin (Derived Thrombin Generation)

Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample. Cmin is the minimum plasma activity/concentration.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · nM
Cmin (Derived Thrombin Generation)
nMEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Cmin (Derived Thrombin Generation)13.534 ± 7.630011.543 ± 6.9299
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 114.91 · 95% CI 102.29 to 129.08
SecondaryTmin (Derived Thrombin Generation)

Thrombin generated in the thrombin generation test can be quantified as platelet-rich or platelet-poor plasma using the calibrated automated thrombogram method, which monitors the cleavage of a fluorogenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample. Tmin is the time of Cmin.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmin (Derived Thrombin Generation)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Tmin (Derived Thrombin Generation)3.67 ± 1.1363.64 ± 0.911
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · ANOVA · p = = 0.8554 · Median difference (final values): 0 · 95% CI -0.5 to 0.5
SecondaryAUC0-t (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*Unit/mL
AUC0-t (Tissue Factor Pathway Inhibitor, TFPI)
h*Unit/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC0-t (Tissue Factor Pathway Inhibitor, TFPI)56.1828 ± 7.9106055.7851 ± 8.43154
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 100.86 · 95% CI 99.27 to 102.47
SecondaryAUC0-inf (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*Unit/mL
AUC0-inf (Tissue Factor Pathway Inhibitor, TFPI)
h*Unit/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC0-inf (Tissue Factor Pathway Inhibitor, TFPI)140.8383 ± 36.06655173.9833 ± 123.89404
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 95.13 · 95% CI 85.7 to 105.6
SecondaryTmax (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Tmax is the time to Cmax

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmax (Tissue Factor Pathway Inhibitor, TFPI)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Tmax (Tissue Factor Pathway Inhibitor, TFPI)1.7500 ± 0.831781.8068 ± 1.20665
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Wilcoxon (Mann-Whitney) · p = = 0.6857 · Median difference (final values): 0 · 95% CI -0.25 to 0.5Median difference is the difference between median tmax in Test IMP versus Reference IMP arms.
SecondaryCmin (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Cmin is the minimum plasma activity/concentration.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · Unit/mL
Cmin (Tissue Factor Pathway Inhibitor, TFPI)
Unit/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Cmin (Tissue Factor Pathway Inhibitor, TFPI)1.261 ± 0.22771.290 ± 0.2288
SecondaryTmin (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Tmin is the time of Cmin.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmin (Tissue Factor Pathway Inhibitor, TFPI)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Tmin (Tissue Factor Pathway Inhibitor, TFPI)16.27 ± 5.27515.55 ± 6.293
SecondaryT1/2 (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI), which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
T1/2 (Tissue Factor Pathway Inhibitor, TFPI)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
T1/2 (Tissue Factor Pathway Inhibitor, TFPI)41.6397 ± 8.6688057.2439 ± 46.13993
SecondaryLambda Zeta (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also releases tissue factor pathway inhibitor (TFPI)\[5\], which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · 1/hour
Lambda Zeta (Tissue Factor Pathway Inhibitor, TFPI)
1/hourEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Lambda Zeta (Tissue Factor Pathway Inhibitor, TFPI)0.0172 ± 0.003230.0148 ± 0.00440
SecondaryAUC%ex (Tissue Factor Pathway Inhibitor, TFPI)

Enoxaparin also release tissue factor pathway inhibitor (TFPI)\[5\], which is thought to contribute to anti-coagulant activity, by inhibiting FXa generation and free FXa. AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · percentage of total AUC
AUC%ex (Tissue Factor Pathway Inhibitor, TFPI)
percentage of total AUCEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC%ex (Tissue Factor Pathway Inhibitor, TFPI)58.9149 ± 5.0741663.0497 ± 8.81000
SecondaryAUC0-t (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC0-t is the area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*IU/mL
AUC0-t (Anti-FXa/Anti-FIIa Ratio)
h*IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC0-t (Anti-FXa/Anti-FIIa Ratio)9.7836 ± 1.752258.7967 ± 1.64043
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 111.39 · 95% CI 105.89 to 117.17
SecondaryAUC0-inf (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity. It was calculated as the sum of AUC0-t plus the ratio of the last measurable value to the elimination rate constant

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · h*IU/mL
AUC0-inf (Anti-FXa/Anti-FIIa Ratio)
h*IU/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC0-inf (Anti-FXa/Anti-FIIa Ratio)9.1620 ± 1.471218.2160 ± 1.60673
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Geometric least square mean ratio: 113.82 · 95% CI 107.47 to 120.53
SecondaryT1/2 (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. T1/2 is the apparent first-order terminal elimination half-life calculated as 0.693/kel.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
T1/2 (Anti-FXa/Anti-FIIa Ratio)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
T1/2 (Anti-FXa/Anti-FIIa Ratio)2.6595 ± 2.065741.9420 ± 1.47865
SecondaryCmin (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Cmin is the minimun plasma activity/concentration.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · UI/mL
Cmin (Anti-FXa/Anti-FIIa Ratio)
UI/mLEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Cmin (Anti-FXa/Anti-FIIa Ratio)0.000 ± 0.0000.000 ± 0.000
SecondaryTmin (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Tmin is the time of Cmin.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmin (Anti-FXa/Anti-FIIa Ratio)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Tmin (Anti-FXa/Anti-FIIa Ratio)0.00 ± 0.0000.00 ± 0.000
SecondaryAUC%ex (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. AUC%ex is the residual area, i.e. the percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · percentage of total AUC
AUC%ex (Anti-FXa/Anti-FIIa Ratio)
percentage of total AUCEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
AUC%ex (Anti-FXa/Anti-FIIa Ratio)0.8078 ± 0.711310.6385 ± 0.52118
SecondaryTmax (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Tmax is the time to Cmax.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · hours
Tmax (Anti-FXa/Anti-FIIa Ratio)
hoursEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Tmax (Anti-FXa/Anti-FIIa Ratio)0.9973 ± 0.284320.9830 ± 0.24467
Statistical analysis
  • Enoxaparin Sodium Chemi (Test IMP) vs Clexane (Reference IMP) · Wilcoxon (Mann-Whitney) · p = = 0.9217 · Median difference (final values): 0 · 95% CI -0.13 to 0.13Median difference is the difference between median tmax in Test IMP versus Reference IMP arms.
SecondaryLambda Zeta (Anti-FXa/Anti-FIIa Ratio)

The ratio of anti-FXa/anti-FIIa activity was calculated for each major parameter. Lambda zeta is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma activity/concentration vs time curve.

Time frame:
At day 1(0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h) and Day 2 (24 and 36h)
Reported as:
Mean · 1/hour
Lambda Zeta (Anti-FXa/Anti-FIIa Ratio)
1/hourEnoxaparin Sodium Chemi (Test IMP)Clexane (Reference IMP)
Lambda Zeta (Anti-FXa/Anti-FIIa Ratio)0.6699 ± 0.521911.0937 ± 1.82862

Adverse events

Collected over Throughout the study: day 1 (pre-dose,0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h), Day 2 (24 and 36h), and post-study follow-up. Follow-up assessments were classified as 'End of study assessments'. They were performed on Day 2, 36 h post-dose, prior to discharging the subject.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enoxaparin Sodium Chemi0/46 (0%)1/46 (2.2%)7/46 (15.2%)
Clexane0/45 (0%)1/45 (2.2%)5/45 (11.1%)
Most frequent serious events
Most frequent serious events
EventEnoxaparin Sodium ChemiClexane
Fibrous dysplasiaCongenital, familial and genetic disorders0/461/45
CellulitisInfections and infestations1/460/45
Most frequent other events
Most frequent other events
EventEnoxaparin Sodium ChemiClexane
HeadacheNervous system disorders2/461/45
DizzinessNervous system disorders1/461/45
SyncopeNervous system disorders1/461/45
NauseaGastrointestinal disorders0/461/45
Ligament sprainMusculoskeletal and connective tissue disorders0/461/45
Urinary tract infectionInfections and infestations0/461/45
Abdominal pain upperGastrointestinal disorders1/460/45
EczemaSkin and subcutaneous tissue disorders1/460/45
Back painMusculoskeletal and connective tissue disorders1/460/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test IMP - Reference IMPReference IMP - Test IMPTotal
<=18 years000
Between 18 and 65 years242347
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Test IMP - Reference IMPReference IMP - Test IMPTotal
Female131124
Male111223
Region of Enrollment
Region of Enrollment(participants)Test IMP - Reference IMPReference IMP - Test IMPTotal
United Kingdom242347
08

Study locations

1 site
  • Simbec Research Ltd
    Merthyr Tydfil, CF48 4DR, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Dec 2014, 4 months.

Results were first posted in Oct 2020, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2014
First posted
Sep 5, 2014
StartActual
Aug 4, 2014
Primary completionActual
Dec 5, 2014
CompletionActual
Dec 5, 2014
Results first posted
Oct 20, 2020
Last update
Oct 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02232802
Lead sponsor
Chemi S.p.A.
Responsible party
Sponsor
First posted
Sep 5, 2014
Start date
Aug 4, 2014
Primary completion
Dec 5, 2014
Completion
Dec 5, 2014
Results posted
Oct 20, 2020
Last update
Oct 20, 2020

Study contacts

Paolo Bettica, MD
study director · Italfarmaco S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin sodium

Start the discussion